Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology
2; 10 cases and grade 3; 14 cases, respectively. Surgery related morbidity was 13.0%
and R0 resection rate was 98.1% (53/54). Grade 3/4 adverse events were acceptable
such as leucopenia (8.9%), neutropenia (17.9%), febrile neutropenia (7.1%), anorexia
(10.7%), and diarrhea (8.9%). There was no treatment related death and no major
surgical complications except for one.
Conclusions: Neoadjuvant DCS chemotherapy demonstrated a high histological
response rate, acceptable feasibility and a sufficient R0 resection rate. This divided
DCS regimen is attractive as NAC for pts with locally AGC.
Disclosure: All authors have declared no conflicts of interest.
683P POSTOPERATIVE RADIOCHEMOTHERAPY WITH
CAPECITABINE FOR GASTRIC ADENOCARCINOMA
M. Skoblar Vidmar
Radiotherapy, Institute of Oncology, Ljubljana, SLOVENIA
Background: Complete removal of malignancy represents the treatment of choice in
nonmetastatic gastric cancer. The Intergroup Study INT-0116 reported a significant
improvment in survival with adjuvant radiochemotherapy. In Slovenia, the program
of adjuvant radiochemotherapy with 5-fluorouracil and leucovorin was introduced
into clinical practice in 2001. Capecitabine is an oral 5-FU prodrug and we assume
that it can replace standard chemotherapy.
Patients and methods: During 2006-2010, 101 patients with the mean age of 59
years, were treated for gastric adenocarcinoma, stage Ib-IIIC, with post-operative
radiochemotherapy with capecitabine. Radical (R0) and non-radical (R1) resection of
the tumor was performed in 97 and 4 patients, respectively. Treatment was started
with the first cycle of chemotherapy with oral capecitabine (1250 mg m 2 twice daily
on day 1-14), radiotherapy with the total dose of 45 Gy was added after 3 weeks.
Patients were irradiated on linear accelerator with 15MV photon beams for five days
per week, at a daily dose of 1.8 Gy. During radiotherapy patients received
capecitabine in lower dose (825 mg/m 2 twice daily, 7 days per week), but one dose
was taken 1 hour before irradiation and the second twelve hours after. Three cycles
of chemotherapy were added after the end of radiotherapy in 3-week intervals.
Results: Postoperative ChT started 2.6–11.3 weeks after surgery (median 6 weeks).
The treatment was completed according to the protocol in 59 patients. No death
occurred due to the therapy. Stomatitis, dysphagia, nausea and vomiting, diarrhea,
hand foot syndrome, stenocardia and alopecia of grade three occurred in 1, 0, 5, 2, 9,
4 and 3 patients, respectively. Some 56 patients lost weight as measured with respect
to the weight they had at the beginning of treatment. The maximum body weight
loss was 18.9% (mean 6.2%). The median follow-up time of 66 survivors was 4 years
(range 2.5-5.7 years). At 5 years, locoregional control (LRC), disease-free survival
(DFS), disease-specific survival (DSS) and overall survival (OS) rates were 95%, 69%,
74%, and 63%, respectively.
Conclusion: In operable gastric carcinoma, postoperative radiochemotherapy with
capecitabine is feasible and its toxicity is low.
Disclosure: All authors have declared no conflicts of interest.
684P RESULTS OF TREATMENT OF LOCALLY ADVANCED GASTRIC
CANCER IN THE ELDERLY PATIENTS
D. Egamberdiev, M. Djuraev, S. Khudayorov, O. Nematov, A. Babaev, H. Tuyev
Abdominal Oncology, National Cancer Center of Uzbekistan, Tashkent,
UZBEKISTAN
Background: Although the incidence of gastric cancer has declined in the general
population, it is the second most frequent cancer in Uzbekistan with its incidence in
the elderly increasing as a result of increased life expectancy. This present study tried
to determine the role of age on outcomes of surgical treatment for gastric cancer in
Uzbek population.
Methods: The study reviewed 288 patients who underwent gasterectomy for locally
advanced gastric cancer. The clinicopathological features of elderly patients (≥75
years, n = 167) and younger patients (